Klaus-Henning Kahl
Hat mitgewirkt an:
-
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
-
Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT
-
Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy
-
V23-6-jD: Prädiktiver Einfluss unterschiedlicher histologischer Subtypen auf die lokale Kontrolle nach stereotaktischer Bestrahlung (SBRT) von Lungenmetastasen bei Patienten mit nicht-kleinzelligem...